Abstract: Disclosed are several preferred embodiments of hydrogen peroxide which are packaged with ease of use and extended shelf-life in mind. The embodiments include foam, mist, gel, and disposable towelette forms of H2O2. Optional ingredients of topical pain relievers and skin protectants are also disclosed, as are their methods of use.

Abstract: The present invention relates to an improved pharmaceutical composition useful for the topical treatment of burns, cuts, wounds, abrasions and the like, and to methods of treatment of injured body surfaces such as skin.

Abstract: We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence.

Abstract: Provided are methods and topical pharmaceutical formulations for the treatment of inflammatory dermatoses. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations are particularly suited to the treatment of acne vulgaris.

Abstract: A composition, which includes ingredients capable of enhancing the immunogenic effect of a vaccine, includes an aluminium salt and at least one ginsenoside, such as a tri-terpenoid glycoside, preferably a tri-terpenoid glycoside of the structure of Rb1. In one particular embodiment, the aluminium salt is Al(OH)3. A kit for use as adjuvant or co-adjuvant of an immunogenic composition includes the composition. The use of such a tri-terpenoid glycoside in the manufacture of a pharmaceutical preparation enhanced the immunogenic effect of a vaccine. A pharmaceutical preparation includes the composition and an aluminium salt, such as Al(OH)3 and a pharmaceutically acceptable carrier.

Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.

Abstract: Improved area decontamination products and methods of use thereof are provided which include reactive nanoparticles (e.g., metal oxides, hydroxides and mixtures thereof) with one or more biocides and a liquid carrier for the nanoparticles and biocide(s). The products may be formulated for area decontamination as sprays, fogs, aerosols, pastes, gels, wipes or foams, and the presence of reactive nanoparticles enhances the neutralization of undesirable chemical or biological compounds or agents. The nanoparticles may be from the group consisting of the alkali metal, alkaline earth metal, transition metal, actinide and lanthanide oxides and hydroxides and mixtures thereof. In preferred forms, nanocrystalline oxides and hydroxides of Al, Ca, Ce, Mg, Sr, Sn, Ti and Zn are employed having single crystallite sizes of up to about 20 nm and surface areas of at least about 15 m2/g.

Abstract: A topical composition and method for the treatment of the symptoms of diaper rashes and skin irritations caused by acidic secretions comprising a) a pH-raising ingredient selected from the group consisting of sodium hydrogen carbonate (bicarbonate of soda), magnesium hydroxide, calcium carbonate, aluminum hydroxide, and mixtures thereof; b) an anhydrous base ointment; c) polysorbate 80; d) a pharmaceutically acceptable diluent; and e) butylated hydroxy toluene, wherein said pharmaceutically acceptable diluent is purified water. The pH of the topical composition is adjusted by adding droplets of glacial acetic acid. The composition can also further comprise AQUAPHOR™. Embodiments disclosed include a cream, dusting powder, spray, bath soak and effervescent tablet, and also the application of the lotion composition to a bodyside diaper liner.

Abstract: A method is provided for destroying oocysts, and destroying or inactivating sporozoites contained within the oocysts, by contacting the oocysts with a composition comprising surface-exposed AlOH groups to cause (a) the oocysts to rupture and the contained sporozoites to be released and/or (b) the oocysts to flatten resulting in destruction of the contained sporozoites. Also provided are pharmaceutical compositions, food supplements and items of clothing comprising a composition comprising surface-exposed AlOH groups.

Abstract: The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.

Abstract: Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an adjuvanting effect on an antigen which is greater than the adjuvanting effect attainable by one of the adjuvants alone. An antigen is covalently bonded to a glycolipid analog to provide a discrete molecule which exhibits an enhanced adjuvanting effect on the antigen which is greater than the adjuvanting effect attainable in the absence of such covalent bonding.

Abstract: A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide on Haemophilus influenzae type b and tetanus toxoid or diphtheria toxoid, which may be reconstituted from a lyophilized state by the other component. The administration of the multiple component vaccine resulted in no diminution of the immunogenicity of any component as a result of interference by other components of the vaccine.

Abstract: A gel formulation is combined with a bactericidal concentrate which is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 mho with about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The bactericidal liquid concentrate in the amount of 3.5 to 12 ml in one liter of gel formulation is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.

Abstract: A composition for controlling growth of pathological organisms on a plant, said composition comprises an effective amount of one or more of metal ion(s); one or more of chelating agent(s); and phosphorous acid, and/or salt or hydrate thereof, said composition is in an agriculturally compatible carrier or vehicle.

Abstract: Ectoparasites, such as fleas, ticks, mites and lice, are removed from a human or animal host after applying a composition that causes the temperature of the treated area to become higher or lower than normal. In one embodiment, treatment is effected by applying a composition that releases heat when contacted with water. The elevated or decreased temperature immobilizes the parasites and facilitates their mechanical removal, such as by combing.

Abstract: The present invention relates to a novel process for the rehydration of magaldrate powder by mechanical processing of aqueous suspensions of magaldrate powder.

Abstract: Methods and pharmaceutical compositions for protecting pharmaceutical compounds (or drugs) in acidic environments are provided. Methods of treatment using formulations capable of protecting pharmaceutical compounds in acidic environments are also provided. Formulations provided generally comprise a therapeutically effective amount of at least one pharmaceutical compound, and a pharmaceutically acceptable protectant. The pharmaceutically acceptable protectant of the invention generally comprises a water-soluble acid neutralizer, and a water-insoluble acid neutralizer.

Abstract: A solid orally administrable pharmaceutical dosage form for the treatment of gastric disorders includes a first portion containing a therapeutically effective amount of a histamine H2-receptor antagonist, and a second portion immediately adjacent the first portion without an intervening barrier disposed between the first portion and the second portion, the second portion containing a therapeutically effective amount of an antacid. Physical separation of the active ingredients into two different portions without a separating barrier has been found sufficient to prevent degradation of the histamine H2-receptor antagonist due to contact with the antacid. The invention therefore provides stabilization of a histamine H2-receptor antagonist-antacid combination tablet which is comparable to known multiple portion tablets, but without an intervening barrier between the antacid portion and the histamine H2-receptor antagonist portion.

Abstract: The invention relates to heat stable liquid antacid and/or antigas preparations capable of being pasteurized in the temperature range of 60-100° C. comprising one or more acid neutralizing and/or antigas compounds in an aqueous liquid suspension consisting essentially of hydroxyethylcellulose as a suspending agent.

Abstract: An adjuvant composition which is a stable oil-in-water emulsion comprising a metabolizable oil, one or more surfactants, an antioxidant and a compound to make the emulsion isotonic is described and claimed. The stable emulsion has a hydrophobic-lipophilic balance (HLB) of from about 7.5 to about 10.5 and a particle size of less than 3 &mgr;m. In a preferred embodiment, the stable emulsion comprises 10% volume to volume squalene, 0.09% weight to volume PLURONIC F-68 block co-polymer, 1.9% weight to volume egg phosphatidyl choline, 1.75% volume to volume glycerol and 0.05% weight to volume &agr; tocopherol. The preferred emulsion has a HLB of 8.0 and a particle size of about 0.2 &mgr;m. In a particularly preferred embodiment, the stable emulsion is combined with an attenuated lipid A derivative such as monophosphoryl lipid A or 3-deacylated monophosphoryl lipid A to enhance the adjuvanticity of the composition.

Abstract: A topical composition and method for the treatment of the symptoms of diaper rashes and skin irritations caused by acidic secretions comprising a) a pH-raising ingredient selected from the group consisting of sodium hydrogen carbonate (bicarbonate of soda), magnesium hydroxide, calcium carbonate, aluminum hydroxide, and mixtures thereof; b) an anhydrous base ointment; c) polysorbate 80; d) a pharmaceutically acceptable diluent; and e) butylated hydroxy toluene, wherein said pharmaceutically acceptable diluent is purified water. The pH of the topical composition is adjusted by adding droplets of glacial acetic acid. The composition can also further comprise AQUAPHOR™. Embodiments disclosed include a cream, dusting powder, spray, bath soak and effervescent tablet, and also the application of the lotion composition to a bodyside diaper liner.

Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

Abstract: A liquid, water-repellent, substantially anhydrous, spray-pumpable skin protectant composition is disclosed. The composition is designed for spraying directly onto skin, has suitable adherence to the skin, and resists running. The composition contains one or more actives, one or more rheology modifiers, and a carrier. The rheological modifiers can be waxes and/or associative thickeners such as some forms of silica. The carrier can be mineral oil replacement (e.g., isohexadecane, cyclomethicone). Film-forming components also help the composition resist running. One indication for which the composition may be formulated is diaper rash. The active ingredient for diaper rash may be dimethicone and preferably also zinc oxide.

Abstract: This invention relates to a buffered phosphorus containing solution comprising at least one phosphorus compound selected from the group consisting of phosphorous acid, hypophosphorous acid, polyphosphorous acid polyhypophosphorous acid, and salts thereof. The solution also contains a buffer including an organic base in the form of a nitrogen containing compound and its conjugate acid. The solution may be used as a fertilizer or as a fungicide. The invention also relates to a method of preparing such a solution.

Abstract: A method for treating wood, characterized by impregnating wood with a metal-containing treating agent containing lignin and/or lignin derivatives and a metal, a metal compound, and/or a metal ion and oxidizing and/or macromolecularizing of the lignin and/or lignin derivatives in the wood to fix the metal component in the wood, and wood and woody materials obtained by the treating method. According to the method of the present invention, while effectively utilizing lignins, lignosulfonic acids, or lignosulfonic acid salts, leaching of the metal component can be suppressed to a low level to thereby retain the effects due to the incorporation of the metal components for a prolonged period.

Abstract: A cataplasm comprising crosslinked polymer gel containing vitamin C or a derivative thereof and a support, wherein the gel is formed by crosslinking a polymer with two kinds of substances selected from magnesium aluminometasilicate, dried aluminum hydroxide gel and aluminum chloride is prepared.

Abstract: The present invention provides an oral dosage form for delivering active agents having a soft core with an active agent particles, which have an average size of greater than about 50 &mgr;m, and a brittle shell encasing the soft core, wherein the weight ratio of drug particles to shell being from about 1.0:0.5 to about 1.0:15.

Abstract: The present invention relates to an orally administered composition to relieve stress comprising from about 100 mg to about 2000 mg of at least one antacid, about 50 mg to about 500 mg of at least one anxiety reducing compound wherein the amount of anxiety reducing compound is based on a concentrated extract containing not less than 0.5% of the essential oil of the respective anxiety reducing compound, and about 20 mg to about 600 mg of at least one mental alertness inducing compound wherein the amount of the mental alertness inducing compound is based on a concentrated extract of the respective mental alertness inducing compound. The anti-stress compositions simultaneously provide the user with a considerable sense of well-being by providing relief from excess gastrointestinal acidity, reducing anxiety, and increasing mental alertness or thinking ability. The overall sense in the user is that stress is reduced emotionally as well as physically as a result of the effects of the present invention.

Abstract: The present invention relates to an orally administered sleep inducing antacid composition comprising from about 100 mg to about 2000 mg of at least one antacid, and about 300 mg to about 1000 mg of at least one sleep inducing compound wherein the amount of sleep inducing compound is based on a concentrated extract containing not less than 0.5% of the essential oil of the respective sleep inducing compound. The advantage of the sleep inducing antacid compositions are that they promote drowsiness and provide relief from excess gastrointestinal acidity.

Abstract: A composition comprising a compound selected from the group consisting of compounds of the following structural formula (1A): and the protonated and quaternized derivatives thereof of the following structural formula (1B): wherein R1 is a C2 to C22 hydrocarbyl group or is an ether group of the formula R—O—(R3)v—C3H6—, where v is 0 to 10 and R is a C1 to C22 hydrocarbyl group; R2 is hydrogen or a C1 to C22 hydrocarbyl group, or is  and (R3)yH, where y is 1 to 100; each R3 is independently selected from a group consisting of an ethylene oxide group (C2H4O), a propylene oxide group (C3H6O), a butylene oxide group (C4H8O) and mixtures thereof; each R4 is a C3 to C2, hydrocarbyl group; R5 is hydrogen or a C1 to C8 hydrocarbyl group; and x is 1 to 100; and A− is an anion.

Abstract: What is shown is an animal blood anticoagulant compound useful in the meat packing industry generally, and in slaughterhouse operations, particularly. The anticoagulant is effective when diluted with water at higher dilution ratios than earlier anticoagulants. In some field trials, this anticoagulant was at least as effective as previously known commercial anticoagulants when diluted by an additional 30%. The present anticoagulant preparation concentrate is an aqueous mixture of soft water (55.0%-65.0/%, w/w); tetrasodium ethylene diamine tetraacetate (Na4EDTA) (0.5%-3.0%, w/w); sodium hexametaphosphate (17.0%-24.0%, w/w); citric acid (5.0%-9.0%, w/w); and sodium hydroxide (4.0%-7.0%, w/w) to obtain a balanced pH that provides optimal chelating and anticoagulant activity. Optimal anticoagulant performance has been found to occur in the range of between pH 6.6 and pH 7.2.

Abstract: The concentrate is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 microhmo to about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The liquid concentrate is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.

Abstract: This invention describes an influenza virus vaccine containing an influenza virus antigen obtained from a cell culture, with an influenza virus antigen content between 1 &mgr;g and 5 &mgr;g per dose and aluminum as an adjuvant as well as a method for its preparation.

Abstract: The invention deals with phosphate water solution with cold solidification capacity. Phosphate composition containing iron oxide solution in acid, water, advantages from the following properties; it contains orthophosphorus acid and in addition metal powder. Phosphate composition is ecologically pure product, non toxic, non cancerogenic, non-allergic. It has antimicrobial, antivirus and fungicidal properties. Phosphate composition can be applied within medicine: surgery, dermatology, dentistry, oncology, pharmacology and other branches. In agriculture use: as a means of curing plant diseases, within veterinary—as a means for preventive maintenance and curing of animal diseases, within construction—as an anticorrosive, fire-resistant, hydro-electric isolating covers, ceramic tiles, concretes, which protect against radiation, as well as for producing other composite materials.

Abstract: A pharmaceutical, orally applicable composition is disclosed, whereby the composition contains at least one antacid active substance as well as more than 45% by weight of a sugar and/or sugar alcohol and between 12% and 35% by weight of water. The composition has a liquid or a semisolid consistency and is substantially free of preservatives.

Abstract: Novel herpes simplex (HSV) vaccine formulations are provided. These comprise HSV glycoprotein gD or immunological fragments in conjunction with 3 Deacylated monophosphoryl lipid A.

Abstract: A method for measuring fat assimilation, such as fat digestion and fat absorption, in a person is provided comprising feeding the person labeled fat, nonabsorbable marker, and a means for coloring stool; allowing the fat, marker and stool coloring means to travel through the digestive tract of the person; monitoring stool from the person for the appearance of the coloring means; collecting stool containing the coloring means; and measuring the amount of marker and labeled fat in the stool to determine the portion of fat digested and/or absorbed by the system. Also provided is a formulation to facilitate one-step administration and specimen collection of a fat-digestion and fat-absorption determinant.

Abstract: The present invention provides NAD-independent Mycoplasma synoviae of strain MS1. The invention also refers to microbiological cultures comprising Mycoplasma synoviae of this strain. Next to this, the invention refers to live vaccines derived from these strains, for the protection of poultry against Mycoplasma synoviae infection. Furthermore, the invention provides methods for the preparation of such vaccines. Also, the use of NAD-independent Mycoplasma synoviae strains for the preparation of live vaccines for the protection of poultry against Mycoplasma synoviae infection is disclosed.

Abstract: Liquid antacid compositions containing a tri- or di-ester buffer have a reduced final product pH providing for a more efficacious preservative system and better tasting product without compromising to acid neutralization capacity of the antacid.

Abstract: Calcium carbonate liquid antacid compositions containing one or more pH adjusting agents to maintain the pH above 9.0, preferably above 9.5. The resultant antacid liquid possesses superior resistance to microbial attack and enhanced taste properties.

Abstract: The invention describes an oral anti-acid paste comprising anti-acid compound in a slow releasing carrier medium which disperses the anti-acid, and releases the anti-acid from the paste upon contact with the aqueous media such as saliva. The paste can be used by placement in the mouth for slow release of the anti-acid into the saliva thereby contacting the mucosa of the esophagus to inhibit irritation to the mucosa due to excess acid.

Abstract: An essentially translucent antacid composition is formed by an aqueous colloidal aluminum hydroxide gel wherein the average particle size of the aluminum hydroxide is less than about 0.5 microns, preferably less than about 0.1 microns, and more preferably less than about 0.01 microns. The suspension is further preferably mixed with a polyol, such as sorbitol or maltitol, to enhance the translucency. The weight ratio of polyol to aluminum hydroxide gel (USP) ranges from about 0.5:1.0 to about 4.0:1.0.

Abstract: A pharmaceutical, oral composition of a liquid to semisolid consistency is disclosed, wherein the composition, substantially free of preservatives, contains at least one antacid active substance as well as more than 45% by weight, a sugar and/or sugar alcohol, relative to the ready-to-use composition, and up to 40% by weight, a pharmaceutically harmless solvent, relative to the ready-to-use composition.

Abstract: Novel pharmaceutical suspensions comprising a pharmaceutically active ingredient suspended in aqueous media with a suspending agent comprising attrited microcrystalline cellulose coprocessed and at least partially surface coated with a calcium sodium alginate salt complex barrier dispersant and readily dispersible and hydratable dry formulations thereof are described and exemplified.

Abstract: An aqueous cosmetic composition containing uric acid in a stably solubilized state together with 0.01 to 1.3% by weight of one or more amphoteric surfactants selected from the group consisting of (a) lauric acid amide propyl betaine, (b) alkyl carboxymethyl hydroxyethyl imidazolinium betaine, (c) coconut oil fatty acid amide propylmethylaminoacetic acid betaine, (d) sodium salt of coconut oil fatty acid acyl carboxymethyl hydroxyethyl ethylenediamine, (e) lauryl dimethylaminoacetic acid betaine and (f) coconut oil alkyl betaine, an alkali and water. The composition is adjusted to pH equal to or higher than pK.sub.1 of uric acid with the alkali to solubilize uric acid. A method for stably solubilizing uric acid in an aqueous cosmetic composition is also disclosed.

Abstract: A solid oral dosage form for the treatment of gastrointestinal disorders comprising a therapeutically effective amount of a therapeutically effective amount of guanidinothiazole compound; and a therapeutically effective amount of an antacid wherein the pharmaceutical and an antacid are separated by a barrier which is substantially impermeable to an antacid.

Abstract: Hydrolyzed gelatin has been found to provide an improvement in taste and mouthfeel when incorporated in small amounts into chewable tablets containing ingredients requiring taste masking. Medicinals and nutritional supplements may now be prepared as chewables for those who find tablets difficult to swallow, for example children and older adults, or for those who prefer the convenience. There is a particularly large improvement in the taste and mouthfeel of chewables incorporating magaldrate and/or calcium carbonate.

Abstract: Compositions for use in the regulation of subnormal pH values in intestinal tract and for treatment of bowel diseases. The compositions comprise a coating and a substantially insoluble alkaline material confined within said coating, the composition being adapted so as to ensure the availability of an amount of said pH regulating alkaline material in the lumen of the gastrointestinal tract exhibiting subnormal pH values. E.g. In the proximal small intestine, the mid small intestine, the distal small intestine, the caecum, the ascending colon, the transverse colon, the descending colon, the sigmoid colon and/or the rectum. The compositions may also comprise a medicament for treatment of bowel disease, e.g. 5-aminosalicylic acid for the treatment of Crohn's disease and colitis ulcerosa. The administration may be oral composition or enemas or suppositories.

Abstract: A substance produced from a combination of acid based ingredients and a mole attracting herb. Placement of the substance into a mole tunnel attracts the mole and upon contact with the substance becomes repelled by the acid taste.

Abstract: The present invention discloses mammalian vaccine compositions having an effective amount of an adjuvant, the adjuvant comprising squalene or squlane, one or more phospholipids and a surfactant. These compositions also optionally contain an aluminum salt and one or more pharmaceutically acceptable buffers.